The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Prophylactic dexamethasone use with CAR-T therapy: real-world practice and outcomes
Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, discusses real-world practice patterns and outcomes with the use of prophylactic dexamethasone to minimize toxicities associated with CAR-T therapy. In cohort 6 of the ZUMA-1 trial (NCT02348216), it was found that prophylactic dexamethasone decreased the occurrence of severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), without negatively impacting CAR-T efficacy. Dr Bansal highlights real-world patterns observed in various centers across the US, and explains that more research is needed before this is universally implemented in clinical practice. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
